objectives In a previous study performed by our group, Strongyloides stercoralis infection in patients with Chagas disease was associated with higher proportion of Trypanosoma cruzi DNA detection in peripheral blood. The aim of the study was to confirm this association in a larger cohort of patients.
Introduction
Strongyloides stercoralis is an intestinal nematode with a wide geographical distribution, affecting 80-100 million people in tropical areas, although it may also be transmitted in regions outside of the tropics of Capricorn and Cancer, such as southern Europe and the south-eastern states of the USA [1] . While more attention is given to other soil-transmitted helminths (such as Ascaris lumbricoides, hookworms and Trichuris trichiura), strongyloidiasis is becoming an emerging global infection, which is underestimated in many countries [2] . Due to the increase in migration and international travel during the last decades, strongyloidiasis is being increasingly diagnosed out of endemic areas, becoming a worldwide disease [3] [4] [5] .
Strongyloides stercoralis infection is asymptomatic in most patients, but patients may present gastrointestinal symptoms (diarrhoea, constipation or abdominal pain), respiratory symptoms and dermatological manifestations, such as urticarial rash and larva currens [1] . Interestingly, this parasite has the ability to persist in the human host for decades due to its autoinfection life cycle, which is partly controlled by the host immune system. However, some immunosuppressant conditions may amplify this autoinfective cycle, leading to severe and even lethal presentations such as the S. stercoralis hyperinfection syndrome and the disseminated strongyloidiasis [6] . Most frequent immunosuppressant conditions related to these severe presentations are corticosteroid therapy, solid organ or bone marrow transplantation and human T-lymphotropic virus I infection [7] .
As other helminths, S. stercoralis infection may modulate the host immune system, changing the Th1/Th2 polarisation [8] . Helminth infections in humans may modify the immune response to other infections or even the antibody production after vaccination [9, 10] . Some examples of how S. stercoralis may modify the immune response against other infections have been described in tuberculosis or malaria [11] [12] [13] . Our group has recently reported how a helminth infection (mostly strongyloidiasis) may modulate the microbiological findings in patients with chronic Chagas disease: S. stercoralis infection was associated with significantly higher proportion of positive T. cruzi DNA detection in peripheral blood [14] .
The aim of this study was to confirm this association between Strongyloides stercoralis infection and T. cruzi DNA detection in a large cohort of blood donors with Chagas disease.
Materials and methods
This cross-sectional study was carried out at Vall d'Hebron University Hospital (VHUH), a tertiary hospital included in the International Health Program of the Catalan Health Institute (PROSICS Barcelona, Spain), and the Catalan Blood and Tissue Bank (BST: Banc de Sang i Teixits, Barcelona, Spain). Since 2005, screening for T. cruzi infection is performed routinely in the BST in blood donors born in, or whose mother was born in, an endemic area and in donors who visited an endemic area [15] . Donors who report Chagas disease or T. cruzi infection during the pre-donation interview were not allowed to give blood. Sera of at-risk blood donors were analysed for T. cruzi antibodies. Chagas disease diagnosis was based upon the positivity of two serological techniques based on different antigen types. T. cruzi Whole Cell Lysate Antigen ORTHO â T. cruzi ELISA Test System (Ortho-Clinical Diagnostics, Raritan, New Jersey, USA) was used in all samples as total native antigen-based test. During the inclusion period, chemiluminescent microparticle immunoassay ARCHITECT CHA-GAS test or PRISM CHAGAS tests were used as recombinant antigen-based tests (Abbott Laboratories, Wiesbaden, Germany); both are based on the same recombinant proteins FP3, FP6, FP10 and TcF. All blood donors diagnosed with Chagas disease during donation screening were consecutively enrolled in the study.
In patients who tested positive for T. cruzi infection, a qualitative real-time polymerase chain reaction (RT-PCR) to detect T. cruzi DNA in peripheral blood was performed according to the method described by Piron et al. [16] . Briefly, total DNA was obtained from 200 ll EDTA blood using High Pure PCR Template Preparation Kit (Roche, Basel, Switzerland) or QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and analysed as triplicates in real-time PCR. T. cruzi negative and positive (T. cruzi Maracay strain epimastigotes were kindly provided by Dr. R. Fisa, Parasitology Laboratory, University of Barcelona, Spain) controls were systematically included in each process of DNA purification and detection. Moreover, an internal control was co-amplified in each PCR to indicate the correct DNA purification and PCR amplification (human Rnase P gene, multiplex PCR). The limit of detection of the real-time PCR was 2 parasites/ml, and the PCR showed a linear curve from 10 5 down to 10 parasites/ml of blood with a four-log dynamic range.
Demographic data (sex, age, country of origin) and T. cruzi serology and PCR results were collected before anonymisation of serum samples from Chagas disease positive blood donors diagnosed from 2005 to 2015 in the BST. Subsequently, serum samples were sent to the Microbiology Department of the VHUH, where S. stercoralis serology was performed.
Strongyloides stercoralis infection diagnosis was based on the detection of serum IgG anti-S. stercoralis by ELISA (SciMedx Corporation, Denville, NJ, USA). Serology was performed following manufacturer instructions. In brief, the kit includes microtiter wells coated with the soluble fraction of S. stercoralis L3 filariform larval antigen. In this study, we used a cut-off value of 0.200; the test was considered positive if the index (ratio of optical density [OD] measure of the sample and 0.200) was >2. Based on a previous study where a similar serological test was used (IVD-ELISA), results were also analysed taking an index cut-off of 2.5, which yields a specificity of 100% for confirmed strongyloidiasis diagnosis [17] .
The STROBE statement guidelines were used to improve the quality of the study. Procedures were performed in accordance with the ethical standards laid down in the Declaration of Helsinki as revised in 2013. Written informed consent was obtained from all patients at the time of blood donation, and the study protocol was approved by the Ethical Review Board of the Vall d'Hebron University Hospital (Barcelona, Spain).
Although all patients who tested positive for T. cruzi antibodies detection were included, a sample size was estimated to ensure enough statistical power. Based on our previous study, we assumed that if positive T. cruzi RT-PCR percentage was 35% and 75%, respectively, 23 patients per group would provide >80% power to show significant differences between the two groups (at a < 0.05). Categorical data are presented as absolute numbers and proportions, and continuous variables are expressed as medians and ranges. The Chi-square test was used to compare the distribution of categorical variables, and the Mann-Whitney U-test for continuous variables. A multivariate analysis using a binomial logistic regression model was carried out. Results were considered statistically significant if the two-tailed P value was <0.05. SPSS software for Windows (Version 19.0; SPSS Inc, Chicago, IL, USA) was used for statistical analyses.
Results
Overall, 202 blood samples from blood donors tested positive for T. cruzi infection during the study period. The blood donors had a median age of 38 (18-62) years, and 121 (59.9%) were women. Most of them were born in Bolivia (156 patients, 77.2%). Information about the country of origin of all included patients is summarised in Table 1 . All patients were born in Latin American countries, except for six (3%) patients who were born in Spain: four patients had been living for many years in endemic area (three in Argentina and one in Venezuela), and two patients were Spaniards whose mother was born in Bolivia (without history of previous travel to endemic area, revealing a mother-to-child transmission).
Testing for T. cruzi DNA in peripheral blood by RT-PCR revealed 72 (35.6%) patients as positive. S. stercoralis serology was positive in 22 (10.9%) patients, of whom all but one Venezuelan were originally from Bolivia. All blood donors with T. cruzi-positive PCR gave a PCR signal outside and below the dynamic range of the test that indicated low parasitaemia (<10 parasites/ml). When comparing both, the group of patients with positive serology (taking an index cut-off of 2) had a higher proportion of positive T. cruzi RT-PCR (54.5% vs. 33.3%, P = 0.050) and a higher proportion of Bolivians (95.5% vs. 75%, P = 0.031) than the group with negative S. stercoralis serology (see Table 2 ). Multivariate analysis showed no differences regarding positive T. cruzi RT-PCR and proportion of patients with Bolivian origin between the two groups.
When taking a serological index cut-off of 2.5 (which increases the specificity of the test to detect a confirmed strongyloidiasis), the difference in the proportions of positive T. cruzi RT-PCR between both groups increased (60% among those with positive serology vs. 33% among those with negative serology, P = 0.017). Differences regarding Bolivian origin were also observed (75.3% vs. 95%, P = 0.050). However, after multivariate analysis, only differences in positive T. cruzi RT-PCR proportion were observed (P = 0.049).
Discussion
In this study, we present a group of 202 patients with Chagas disease diagnosed during the BST screening, in whom the proportion of patients with positive S. stercoralis was 10.9% (22 patients). Patients with positive S. stercoralis serology showed statistically significant greater proportion of positive T. cruzi RT-PCR than those with negative S. stercoralis serology (54.5% vs. 33.3%). These findings are in accordance with the results obtained by our previous study performed in a smaller group (66 patients) of patients with Chagas disease, where the group of patients with helminth co-infection (strongyloidiasis in most of the cases) had a greater proportion of positive T. cruzi RT-PCR than the group without helminth co-infection (75% vs. 35.2%) [14] .
The characteristics of this group of patients with Chagas disease are rather similar to the ones described in other series in Europe, with young age, predominance of females and Bolivia as most frequent country of origin [18] [19] [20] . Scarce information about the prevalence of S. stercoralis infection in Bolivia is available, and it comes from studies centred on at-risk populations [21] . However, studies performed in Bolivian immigrants living in Spain showed a S. stercoralis seroprevalence of 18-44% [14, 22] . Another study performed in Switzerland showed a S. stercoralis seroprevalence of 8.4% among Latin American immigrants (48% from Bolivia) [23] . Hence, taking into account the prevalence of Chagas disease and strongyloidiasis in the Bolivian population, coinfection is likely to be frequent. In fact, Bolivian origin could be a confounder; however, in the multivariate analysis in our study, only differences in the positive T. cruzi RT-PCR proportion were observed between the two groups.
The effect of S. stercoralis infection in the host response to other infections has been described in other situations. In a study performed in five hamlets of the western border of Thailand, helminth-infected villagers (including those with S. stercoralis infection) were more likely to develop Plasmodium falciparum malaria in the following months, with an adjusted risk ratio of 2.24, and the risk of developing malaria increased with the number of helminth species [11] . Similar results were found in Ethiopia in patients with and without tuberculosis; prevalence of intestinal helminths (being S. stercoralis one of the most frequent one) was 71% in patients with tuberculosis and 36% in healthy household contacts, yielding an odds ratio of 4.7 [12] . A study performed in the same setting showed that patients with tuberculosis and helminth co-infection had a lower rate of sputum smear positivity than those without helminth co-infection [13] . More examples of the helminth coinfection effect have been described in HIV-infected patients in the tropics, where the presence of intestinal nematodes is associated with decreased CD4+ T-cell count even under antiretroviral treatment [24] . And more interestingly, Ascaris lumbricoides treatment in HIVinfected patients without receiving antiretroviral therapy had a significant effect on CD4+ T-cell count increase [25] . Previously to the study already published by our group, where the effect of helminth infection (strongyloidiasis) on the detection of T. cruzi DNA in peripheral blood in T. cruzi chronically infected patients was observed, no other study has addressed the possible interaction of these parasites in humans [14] . However, this relationship had been previously described in animal model studies. Monteiro et al. described higher prevalence of T. cruzi-positive blood cultures in golden lion tamarins infected with T. cruzi when they were co-infected with intestinal helminths of the Trichostrongylidae family [26] . In the same way, in a study performed with T. cruzi-infected mice, Taenia crassiceps co-infected mice showed significantly higher parasitaemia than non-co-infected ones [27] . All these findings could be explained by the different immune response of the host against these two parasites. S. stercoralis infection, as other helminth infections, induces a Th2 immune response and regulatory cytokine induction (IL-10 production), leading to a suppression of proinflammatory cytokines and diminishing Th1 immune response [8] . Conversely, these pro-inflammatory cytokines (Th1 response) are present in the acute phase of Chagas disease [28] . This kind of parasite co-infection may modulate the immune response of the host against them, resulting in changes in the clinical and microbiological presentation of the infection. Further studies are needed to evaluate the specific changes in the immune response in patients with Chagas disease that have a helminth co-infection.
Hence, taking into account the results of the present study, the results of the previous published study by our group and the studies in animal models, we can conclude that helminth infection (and specifically S. stercoralis infection) increases the probability of having a positive T. cruzi RT-PCR in patients with Chagas disease [14, 23, 27] . This interesting finding may have important repercussions, as molecular techniques to detect T. cruzi DNA are increasingly being used in the post-treatment followup of patients with Chagas disease, especially in clinical trials that evaluate new antitrypanocidal drugs or new therapeutic regimes [29, 30] . Being aware of the high prevalence of strongyloidiasis in areas where Chagas disease is endemic (and specifically in Bolivia), the possible co-infection should be investigated to better interpret the microbiological follow-up of patients with Chagas disease.
As this study is performed with blood bank archived and anonymised samples, there were some limitations: scarce clinical information of the patients is available, and some of them could have received specific treatment before blood donation, which may modify the probability to detect T. cruzi DNA. However, this fact is unlikely, as individuals are asked in the pre-blood donation questionnaire specifically about Chagas disease, and any report of a previous history of T. cruzi infection leads to deferral from blood donation. Another possible limitation is that S. stercoralis infection diagnosis has relied upon the positivity of serological tests, which is not a confirmatory diagnosis, as it may reflect a past infection or a crossreaction with other nematodes. Nevertheless, based on previous studies, we have used a higher serological index cut-off to overcome this issue, as an index cut-off of 2.5 has specificity near 100% for confirmed S. stercoralis infection diagnosis [17] . It is important to note that even though the serological test used in our study is very similar to that used in the study by Bisoffi et al.
(an IVD-ELISA), it is not exactly the same test, and interpretation of results has to be made with caution. In summary, we found a S. stercoralis seroprevalence of 10.9% among this group of patients with Chagas disease detected during screening in blood donors. Interestingly, patients with positive S. stercoralis serology had a higher proportion of positive T. cruzi RT-PCR in peripheral blood than those with negative serology, which reflects the potential immunomodulatory effects of S. stercoralis in patients co-infected with T. cruzi. Although larger and more in-depth studies are needed to better understand this protozoan-helminth interaction, it should be taken into account in situations where the detection of T. cruzi DNA is used as a tool to evaluate new diagnostic tests or new antitrypanocidal drugs, especially in clinical trials.
